Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
Brefeldin A (BFA) (HB2949)
Description:Reversible protein transport inhibitor. Commonly used in cytokine staining. Enhances CRISPR-mediated HDR.
Purity:>98%
- Description:
Novel, intracellular covalent chemokine CCR2 negative allosteric modulator (NAM). Binds irreversibly.
MCC950 sodium salt (HB4636)
Description:Potent, selective NLRP3 inflammasome inhibitor
Purity:>98%
Pam3CSK4 (HB3428)
Description:TLR1/TLR2 agonist and potent NF-κB activator. Induces cytokine production.